Trained Market Monkey

Maurice was discovered mid-swing from his monitor to his banana-peel-covered whiteboard, muttering something about “approval paradoxes” and “why does good news smell like rotten fruit?”

There’s a peculiar moment in biotech investing—rare as a perfectly ripe banana—where everything you’ve been waiting for finally happens, and the market responds by throwing its own bananas at you. Not the celebratory kind. The angry kind.

That’s where we find ourselves with Rocket Pharmaceuticals (RCKT), a late-stage gene therapy company that just scored FDA accelerated approval for KRESLADI, its lead therapeutic for severe Leukocyte Adhesion Deficiency-I (LAD-I) in children. It’s a genuine milestone. A real drug. Real FDA approval. Real commercial potential for a devastating rare disease where patients’ immune systems basically surrender.

And yet, the stock got pummeled. Down 8.9% on the news. Institutional confidence? Foxy sees it brewing like overripe bananas ready to ferment into something profitable. I’m sitting here with my tiny reading glasses, trying to understand why the market is currently pricing this like yesterday’s fruit.

Let me explain what’s actually happening here—and why this might be one of those rare moments where pessimism creates opportunity.

The Paradox Nobody’s Talking About

Gene therapy is the most promising and most anxiety-inducing sector in biotech. It’s like watching someone juggle chainsaws—incredibly impressive when it works, absolute chaos when it doesn’t. Rocket has built itself around two distinct approaches: in vivo AAV programs (therapies that work inside the body) and ex vivo lentiviral programs (cells modified outside the body, then reintroduced).

KRESLADI represents the ex vivo approach, and here’s why the market’s skepticism feels premature: this is a first-in-class gene therapy for severe LAD-I, a disease where kids basically have non-functional immune systems. Their white blood cells can’t properly adhere to blood vessel walls, so infections become life-threatening. These are desperately ill patients. Their families will move mountains for a working therapy.

The approval itself is wild. It’s FDA accelerated approval—the gold-standard fast track for serious diseases with unmet medical needs. That means Rocket gets to start selling KRESLADI while continuing to gather long-term efficacy data. This isn’t a “we hope this works” situation. This is a “we’re confident enough to let patients use it now” situation.

So why did the stock tank? Partially because biotech investors are professionally pessimistic—they’ve been burned too many times. Partially because the rare disease market is, well, rare, so commercial projections look modest compared to the hype cycle. Partially because Rocket’s balance sheet looks like a banana peel someone forgot to throw away: negative free cash flow (-$104.8M annually), a debt-to-equity ratio of 8.97x, and an operating loss that would make a business school professor weep.

But here’s what I’m noticing: that 44.7% momentum surge Foxy mentioned came before the approval. Institutional money saw something. And they weren’t wrong.

Breaking Down What’s Actually Valuable Here

Let’s talk pipeline. Rocket doesn’t have just one shot at redemption. It’s got a whole arsenal:

The in vivo cardiac programs are the crown jewels—RP-A501 for Danon disease (Phase 2), RP-A601 for Plakophilin-2 Arrhythmogenic Cardiomyopathy (Phase 1), and RP-L301 for Pyruvate Kinase Deficiency. These aren’t niche diseases. Danon disease causes progressive heart failure in young people. It kills people. If any of these work—truly work—the commercial opportunity explodes from “rare disease” to “we might actually change standard of care.”

And here’s the thing about gene therapies that the market seems to be forgetting: they’re curative. You don’t need to keep patients on them forever. You treat them once, maybe twice, and they’re potentially cured. That’s different from traditional pharma. Different business model. Different economics. Different risk profile once you prove the concept works.

KRESLADI is that proof of concept. It’s the banana peel that shows the system works. Now Rocket gets to peel the rest of the fruit.

The Wedbush Signal Nobody’s Hearing

Wedbush Securities recently called Rocket “significantly undervalued” based on the advancing cardiac pipeline. That’s not some random analyst throwing darts. Wedbush is a serious shop. When they say undervalued, they mean they’ve modeled the probabilities and think the market is discounting success by too much.

Current price: $3.64. Foxy’s entry target: $4.82. Foxy’s price target: $8.50. That’s based on late-stage clinical catalysts, successful regulatory pathways, and a market that’s currently pricing in too much pessimism.

Let me dig into why the pessimism might be misplaced. Gene therapy has had its failures—I won’t sugarcoat that. But Rocket’s failure rate isn’t in the catastrophic range. The company has been methodical. The programs are grounded in understood biology. LAD-I is a proven-to-work proof of concept.

The risk here is execution. The company needs revenue from KRESLADI to stabilize its cash burn. It needs Phase 2 data from Danon disease to be positive. It needs regulatory pathways to continue opening for cardiac therapies. These aren’t small asks. But they’re not impossible asks either.

The Debt Elephant (And Why It’s Not as Scary as It Looks)

That 8.97x debt-to-equity ratio? Yeah, I threw a banana at my monitor when I first saw it. But then I did the math.

Rocket has a market cap of $395M and negative equity (because accumulated losses exceed assets). So technically, that ratio is about as useful as a chocolate banana peel. The real question is: does the company have enough cash runway to reach profitability, and does its pipeline have enough probability-weighted value to justify waiting?

With KRESLADI now approved and generating revenue, the cash burn trajectory changes. One approved therapy changes everything. One. And Rocket has five more potentially significant programs in clinical development.

The short ratio is 4.64%, which suggests moderate skepticism but not overwhelming bearishness. Institutional ownership is the real tell—and the 44.7% momentum surge before FDA approval is a flashing neon sign that smart money was already accumulating ahead of this catalyst.

The Three-Year Thesis

Here’s how I see this unfolding, and why Foxy’s confidence isn’t misplaced:

Year 1 (2026-2027): KRESLADI ramps commercially—modestly at first because LAD-I is rare (maybe 50-100 eligible patients in the US annually), but meaningful from a cash flow perspective. Danon disease Phase 2 data hits. Market starts re-rating based on approved therapy in hand plus positive Phase 2 signals. Stock moves toward $6-7 range on this pathway.

Year 2-3 (2027-2028): Danon and possibly other cardiac programs advance through regulatory discussions. Revenue from KRESLADI becomes predictable. Rocket approaches cash flow breakeven or better. Street begins valuing this as a commercial-stage company with multiple shots at home runs, not a pre-revenue biotech. Stock hits $8-10 range on successful additional approvals or Phase 3 initiations.

This isn’t guaranteed. Gene therapy is still dangerous territory. But the risk-reward at $3.64, with KRESLADI approved and multiple catalysts ahead, favors the upside.

The Honest Risks (Because Maurice Doesn’t Sugarcoat)

Let me be clear: this is a medium-risk, high-potential-reward situation. Not for faint-hearted investors.

Rocket could fail to commercialize KRESLADI effectively. LAD-I is rare. You need specialized centers. You need patient identification. You need insurance coverage. Any of these could disappoint. Phase 2 data for Danon could be negative or underwhelming. The cardiac programs could hit regulatory snags. The company could burn through cash faster than expected and need dilutive financing.

But here’s what’s already happened: the company proved its core technology works by getting FDA approval. That’s enormous. That’s the fruit that was rotten is now fresh. Everything else is follow-through.

Why the Market’s Being Dumb Right Now

Biotech investors often suffer from “approval approval syndrome”—they spend years waiting for FDA approval, then immediately start worrying about commercialization. They de-risk one thing and immediately re-risk another. It’s like finally getting to eat your banana and immediately worrying it’s not yellow enough.

Rocket just cleared its biggest hurdle. It has a validated technology. It has multiple shots on goal. It’s trading 25% below its 50-day moving average on the day of good news. That’s irrational exuberance in reverse.

Foxy’s thesis here is that institutional money will slowly recognize this over the coming months. Not all at once. But as KRESLADI commercial ramp evidence accumulates and other catalysts approach, the market will re-rate.

I’m not saying buy with reckless abandon. I’m saying this is the moment where being greedy when others are fearful actually makes mathematical sense.

Disclaimer: Trained Market Monkey, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys—no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.

COMING NEXT WEEK: Why AI chip stocks are in a “bunch” of trouble—and which ones are about to separate from the peel. Maurice investigates semiconductor seasonality with his patented “Ripeness Indicator.”

Maurice’s final wisdom: “Approval doesn’t cure pessimism. Only results do. But results start with approval. The bananas are already yellow—we’re just waiting for someone to peel them.”